^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ThisCART22

    i
    Associations
    News

    Trials

    Company:
    Fundamenta Therap
    Drug class:
    CD22-targeted CAR-T immunotherapy, T lymphocyte replacement
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (NCT05106946)
    Phase 1
    Fundamenta Therapeutics, Ltd.
    Recruiting
    Last update posted :
    11/11/2021
    Initiation :
    10/25/2021
    Primary completion :
    10/25/2023
    Completion :
    10/25/2024
    CD22
    |
    ThisCART22